|
---|
As Of | Filer | Filing¹ | For·On·As | Docs:Size | Issuer | | Filing Agent | | | | | | | | | |
---|
|
---|
4/9/24 JPMorgan Chase & Co. SC 13G/A© 1:67K Revance Therapeutics, Inc.
1/25/24 JPMorgan Chase & Co. SC 13G/A© 1:67K Revance Therapeutics, Inc.
1/25/24 JPMorgan Chase & Co. SC 13G/A© 1:67K Revance Therapeutics, Inc.
1/27/23 JPMorgan Chase & Co. SC 13G/A© 1:67K Revance Therapeutics, Inc.
1/18/22 JPMorgan Chase & Co. SC 13G/A© 1:67K Revance Therapeutics, Inc.
1/29/21 JPMorgan Chase & Co. SC 13G/A© 1:67K Revance Therapeutics, Inc.
1/17/20 JPMorgan Chase & Co. SC 13G/A© 1:67K Revance Therapeutics, Inc.
1/4/19 JPMorgan Chase & Co. SC 13G/A 1:64K Revance Therapeutics, Inc. Broadridge Fin’l… Inc/FA
1/25/18 JPMorgan Chase & Co. SC 13G/A 1:64K Revance Therapeutics, Inc. Broadridge Fin’l So… Inc
1/11/17 JPMorgan Chase & Co. SC 13G/A 1:39K Revance Therapeutics, Inc.
1/21/16 JPMorgan Chase & Co. SC 13G/A 1:38K Revance Therapeutics, Inc.
12/7/15 JPMorgan Chase & Co. SC 13G 1:38K Revance Therapeutics, Inc.
____________ | ¹ | Filing/Form Type: | | SC 13G | Statement of Acquisition of Beneficial Ownership by a “Passive” Investor — Schedule 13G. | | /A | Amendment to, or Amended version of, a previous Filing of this Type. | | © | This Filing was a Confirming copy. |
|